191 related articles for article (PubMed ID: 33462360)
1. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.
Verkouteren BJA; Wakkee M; Reyners AKL; Nelemans P; Aarts MJB; Rácz E; Terra JB; Devriese LA; Alers RJ; Kapiteijn E; van Doorn R; Bekkenk MW; Reinders MGHC; Mosterd K
Br J Cancer; 2021 Mar; 124(7):1199-1206. PubMed ID: 33462360
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
4. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
6. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
9. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
Tong J; Mitchell B; Roth K; Logan D; Ernst S
J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
[TBL] [Abstract][Full Text] [Related]
11. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
[TBL] [Abstract][Full Text] [Related]
12. Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma.
Marescassier H; Dousset L; Beylot-Barry M; Célérier P; Vaillant L; Bedane C; Leclère F; Wierzbicka-Hainaut E; Masson Regnault M
Dermatology; 2021; 237(6):1023-1028. PubMed ID: 33472195
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Mesti T; Sever M; Ocvirk J
Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
15. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real-life data.
Gürbüz M; Doğan İ; Akkuş E; Ermiş H; Utkan G; Vatansever S; Taş F
Dermatol Ther; 2021 Nov; 34(6):e15122. PubMed ID: 34478210
[TBL] [Abstract][Full Text] [Related]
17. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
[TBL] [Abstract][Full Text] [Related]
18. Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study.
Bossi P; Peris K; Calzavara-Pinton P; Queirolo P; Alfieri S; Palla M; Rossi MT; Spagnolo F; Tambone S; Astolfi C; Ascierto PA
Future Oncol; 2020 Jun; 16(16):1091-1100. PubMed ID: 32374193
[No Abstract] [Full Text] [Related]
19. Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas.
Rizzo JM; Segal RJ; Zeitouni NC
Photodiagnosis Photodyn Ther; 2018 Mar; 21():58-62. PubMed ID: 29102653
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib for Locally Advanced Basal Cell Carcinoma: Descriptive Analysis of a Case Series and Comparison to the Literature.
Viscusi KS; Hanke CW
J Drugs Dermatol; 2015 Sep; 14(9):956-62. PubMed ID: 26355613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]